forward made the we everyone. morning, us to for cornerstone continue joining you, NEXLETOL NEXLIZET moving reducing cement review quarter as today risk. therapies have to second and meaningful and review cardiovascular Thank the plans to in and you to our Alina, Thank progress during good
areas across of was or patients cardiometabolic building to with the our biopharmaceutical successfully Esperion undeniably at strategic period leading business, into for all and we watershed for executed The outcomes second as a key risk an quarter initiatives improving company, diseases. cardiovascular
The this positions and of greater product and revenue, second NILEMDO partner, termination Oberland. efforts. RIPA, agreement, importantly, partners to quarter significant the NUSTENDI, to in increases optimizing This commercialization purchase or progress European detail our discounted international and Daiichi our double-digit expanding existing in transaction royalties access from DSE; focus monetization U.S. by discuss was on enhances the our by interest Europe, our significantly better Sankyo and transaction our early revenue with later. payoff U.S. us of our strategic transformational balance sheet or to will Ben and highlighted
of me Now our as U.S. momentum expanded year-over-year of quarter and to growth turn received XX% let in by revenue XXXX progress the gaining efforts, new second product sequential was which labels U.S. March. XX% This growth. validated the growth with by in commercialization late our are driven we
Our CD patients prior limited in were had NEXLETOL to a of reduction and a population and on statin were for that LDL-cholesterol event labels NEXLIZET already therapy.
differences: including one, or tolerate unable reduction expands statin population benefits; and patient the significant primary maximize includes X have CV therapy. are to by use labels enables expanded Our that patients three, risk in prevention; two,
both nonstatin the risk the LDL-cholesterol by to patients. CV prevention reduce and are and NEXLETOL of NEXLIZET now oral primary the approved to first in FDA lowering be secondary drugs events
continued payer expanded and is product growth and opportunity drive support and labels patients NEXLETOL these prescriptions to benefits Critical bring million access. broad increased awareness expanded the in the the the NEXLIZET have new of ultimately team. and XX broadened sales prescriptions, under sales we our We eligible labels.
To field to to
with updates that recent new lives label began with management reflect than am report pleased more on place. to criteria finalized in criteria of date, Here, X, payer now we to June updated label I million partnering updates. update to UM The payers to of we work now the XXX major and have the done include criteria have by utilization more To majority XX% were than excellent mid-July, payer updates. UM
We to outcomes XX% clinical our bring aligns and increased patients benefit system preferred resulting economic payer underscores garner the of value and the payers' XX%. preferred labels to our products to our commercial respectively. both also coverage continue coverage, acceptance Medicare health new that formulary coverage strong than greater recognition the with care in and This new
expect of the NEXLETOL product result upcoming a confidence should prescribing and increasing which patient translate NEXLIZET, As enhanced in this into beyond. streamlined quarters we and physician process, increasing in prescription and access sales
we payer HCP about their access CV care ensure are With health to we further HCPs. have In campaign next empowering talk to aimed providers, is commercial educating patients at their our important or a initiative to advancing, tandem, our risk.
gaining We a traction. are tactics are of sales and using marketing variety that and digital traditional
of our has care physicians cardiologists subsets targeting been detailing. example, primary in-person force expanded sales specific For with and
also where XX% of peer-to-peer, gained to point search, care, reach our targeted of meaningful health with We our campaign EHR, team channels, and X banners utilized digital including e-mail, over digital care traction media providers. the social
far. prior and launch weeks truly X we May. year. the weeks used is we throughout last equivalents of have tremendous XX,XXX the HCPs June total this XX% because compared that a and progress This of increasing of result are to weeks scripts, in the by proud As effort, X have prescription approximately sales retail there in care, our X Herculean force initiatives May more this of combined I'll we a and we the teams, writing managed now these were marketing comparison than so note made
are tremendous into to us blockbuster reasons. ahead and We for variety NEXLETOL have NEXLIZET well of build a poised opportunity and of products a
clinical from primary that First reduction supports lipid and and and reducing Outcomes in foremost, efficacy cardiovascular and we study patients. validates lowering have compelling the and data prevention safety CLEAR risk secondary in
options. million need of risk treatment at people patient Second, population there XX is better a large underserved who
market the of all right all and or launches team execution and a this taking confident Finally, we successfully and team's been steps pharmaceutical drive have I'm careers, during in penetrate product are successful a programs strategy led to we because this I the part either say to right people their it. who capabilities. this and have have
Importantly, understanding to methodical rotations like that in we we a pieces this are effort, managing time initial all way, the rotations and and subsequent place be that to need this create The physicians compounds. patients the have We take launch payers, see momentum in a but flywheel. for successful.
will to ultimately, confident that start into increasing are the undertaking we We strong into and are off are a product revenue. today translate scripts and work accelerated
European we NUSTENDI turn where now our Starting internationally. is DSE me the indications these partner, new risk have in label new reductions labels making DSE, approved and which partners prevention areas They be in for with and European strides. patients. XXXX anticipated and with EU, secondary making its begun Italy the the the expanded Commission, for year-end to are launched launching and cardiovascular received most from and lowering reflects LDL-cholesterol progress in Let NILEMDO expanded our territories, XXXX. to primary by important
unable in XX% be levels as LDL-cholesterol patients recommended to up a to of this expect market taking for reach for to guideline statins. are despite substantial Europe DSE We
secondary CV the to primary Europe. first NILEMDO will with non-statin, that cardiovascular reduction, be of as and prevention the NUSTENDI position indications, and risk approved strength able only both confident lipid-lowering are the in and in for We approved DSE medicine
will by at leaders visibility of efforts attended and make Cardiology benefit Consequently, key at opinion from well our meeting commercial ESC States. the this year the end This upcoming also is a U.S. to including globe, our Congress among is enhance the and efforts Congress awareness to have the DSE DSE will month the medical the around presence London. at European United largest products medical the of of we the Society in of expect HCPs. and exciting cardiovascular
in approval Sankyo Beyond and new or Europe, Korea. in Thailand DS NEXLETOL applications gained NUSTENDI submitted ASCA, and our and Macau partner, NILEMDO and Limited, Daiichi for in drug for NEXLIZET Company
our launches. from these these are incremental regions, in we see expect While royalties smaller product growth to
in baseline trial Phase the bempedoic Japan XX partner, Our a Otsuka their Pharmaceutical, of from clinical III endpoint Japanese that acid LDL-cholesterol week hypercholesterolemia. in for announced was at reduction treatment achieved as primary for
second application approval pricing in expected a file Otsuka the with XXXX plans XXXX. of new national in anticipated insurance to drug health half at in Japan
enthusiastic market for substantial in the Japan of momentum markets growth one it be valuable continued as as could the the largest are is well a as This Otsuka a in about for for We future. lipid-lowering Esperion contributor therapies. royalty
in expanding risk cardiovascular for with continues Esperion use Our high reduction of the bempedoic acid to patients in or global risk disease. team cardiovascular for at make reach strides
work year. the our drug advance file and track end to for Australia to and this on continue Israel Canada, in applications new these by submissions are of We
the partner given a additional We collaborations risk believe are market around bempedoic reduction, total worldwide partnerships label and for cardiovascular the with value and for the acid opportunities addressable are we and expansions continually an attractive proposition. for we world, compelling evaluating
and of Journal that of in Finally, predicted to analysis demonstrated of unit the that the a to to is pleased decrease journals we "Comparative support clinical Outcomes X in products. risk bempedoic published Cardiovascular American sets CLEAR risk treatment scientific bempedoic comparable build body reduction published growing in and benefits of we article was knowledge College Acid our are of in acid cardiovascular that the the Statin Drugs," trials. past statin peer-reviewed titled benefit This Benefits have of To cardiovascular of Cardiology. bempedoic that an seen end, data continue acid per the LDL-cholesterol data months, over including
deaths acid the contribution Outcomes global benefit Cardiology. or on Clinical article acid published on and pandemic suggests have COVID of pandemic-related results likely both the was Another of bempedoic analysis confirms trial based MACE-X underestimated represented of the MACE-X pandemic fatalities. impact and Journal may on COVID-XX on that the and conduct in the of the infection This undetermined the benefit of CLEAR bempedoic COVID-XX of that
over and to continue you will at and look updating the medical present forward We on key it progress to meetings data the publish months. our
With financial Ben that progress during the detailed overview the me let quarter. of our a the of turn over to call review Ben? second for business,
